Humira One Year Out: The Largest LOE Event In US Pharma History

Amgen’s Amjevita Biosimilar Set To Launch On 31 January 2023 With Many More To Follow

Ahead of the first biosimilar Humira product set to launch in 365 days, Generics Bulletin provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.

Day 365 Day 1 Turning Blocks Hand
With Humira, the biosimilar market is set to 'ignite' in 2023 • Source: Frank Harms / Alamy Stock Photo

Not that it needed spelling out, but Organon’s CEO Kevin Ali wished to make sure there were no uncertainties.

“That’s going to be the largest loss of exclusivity event in the history of the pharma market in the US,”...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.